Paper Details

  1. Home
  2. Paper Details

Dose-ranging study of riluzole in amyotrophic lateral sclerosis. Amyotrophic Lateral Sclerosis/Riluzole Study Group II.

Author: BensimonG, GuilletP, LacomblezL, LeighP N, MeiningerV

Clinical TrialA clinical trial is a planned study conducted on humans to evaluate the efficacy and safety of pharmaceuticals, medical devices, and treatment methods. It aims to explore the possibilities of new treatments and improve the health of patients.
Comparative StudyResearch that compares multiple groups/interventions to determine differences/similarities in outcomes/characteristics.
Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Multicenter StudyResearch conducted in collaboration with multiple research institutions. It aims to collect a wide range of data and obtain more generalizable results.
Randomized Controlled TrialA clinical trial that randomly assigns participants to treatment and control groups to evaluate the effects of an intervention.

Overview

This study investigates the effectiveness of riluzole, a drug previously shown to slow muscle weakness and decrease mortality in ALS patients, in a double-blind, placebo-controlled, multicenter trial. The study aims to confirm the initial findings and assess the drug's effectiveness at different doses.
Paper Details　
Original Abstract of the Article :
Amyotrophic lateral sclerosis (ALS) is a progressive disease with no effective treatment. In an initial study, riluzole decreased mortality and slowed muscle-strength deterioration in ALS patients. We have carried out a double-blind, placebo-controlled, multicentre study to confirm those findings an...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://doi.org/10.1016/s0140-6736(96)91680-3

データ提供：米国国立医学図書館（NLM）

Riluzole: A Potential Treatment for Amyotrophic Lateral Sclerosis (ALS)

This research investigates the effectiveness of riluzole, a medication used to treat amyotrophic lateral sclerosis (ALS), a progressive neurodegenerative disease. It's like exploring a desert, where every step is a challenge, and finding a way to slow the relentless march of the disease. The researchers conducted a clinical trial to assess the efficacy of riluzole at different doses, comparing its effects to a placebo. They found that riluzole slowed the progression of ALS, reducing mortality and muscle weakness.

Riluzole: A Potential Oasis in the Desert of ALS

The study found that riluzole slowed the progression of ALS, reducing mortality and muscle weakness. It's like finding a hidden oasis in the desert, where riluzole provides a source of water to combat the relentless thirst of this devastating disease. This finding provides hope for patients with ALS and underscores the need for further research to optimize the use of riluzole.

Navigating the Desert of ALS: A Hopeful Journey

This research offers a glimmer of hope for individuals living with ALS. It's like finding a pathway through the desert, where riluzole provides a means to slow the progression of the disease and improve quality of life. This study emphasizes the importance of ongoing research and development of new therapies to combat this devastating disease.

Dr.Camel's Conclusion

This research offers a glimmer of hope for individuals living with ALS, demonstrating that riluzole can slow the progression of the disease and improve quality of life. It's like finding a hidden oasis in the desert, where riluzole provides a source of water to combat the relentless thirst of this devastating disease. This study underscores the importance of ongoing research and development of new therapies to combat this devastating disease.

Date :
  1. Date Completed 1996-08-15
  2. Date Revised 2023-08-15
Further Info :

Pubmed ID

8676624

DOI: Digital Object Identifier

10.1016/s0140-6736(96)91680-3

SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.